Jackson Creek Investment Advisors LLC Makes New $1.43 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Jackson Creek Investment Advisors LLC bought a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 15,498 shares of the biotechnology company’s stock, valued at approximately $1,430,000. Blueprint Medicines makes up about 0.5% of Jackson Creek Investment Advisors LLC’s investment portfolio, making the stock its 17th biggest position.

Several other large investors also recently modified their holdings of BPMC. Bank of New York Mellon Corp grew its holdings in shares of Blueprint Medicines by 1.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 266,744 shares of the biotechnology company’s stock worth $13,396,000 after purchasing an additional 4,127 shares in the last quarter. Brown Advisory Inc. grew its holdings in shares of Blueprint Medicines by 0.9% during the 3rd quarter. Brown Advisory Inc. now owns 641,039 shares of the biotechnology company’s stock worth $32,193,000 after purchasing an additional 5,843 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Blueprint Medicines by 9.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,055 shares of the biotechnology company’s stock valued at $605,000 after buying an additional 1,052 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Blueprint Medicines by 4.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,269 shares of the biotechnology company’s stock valued at $1,872,000 after buying an additional 1,417 shares in the last quarter. Finally, Emerald Advisers LLC boosted its stake in Blueprint Medicines by 22.4% in the third quarter. Emerald Advisers LLC now owns 607,037 shares of the biotechnology company’s stock valued at $30,485,000 after buying an additional 110,984 shares in the last quarter.

Wall Street Analysts Forecast Growth

BPMC has been the topic of several research analyst reports. Citigroup raised their price objective on Blueprint Medicines from $54.00 to $65.00 and gave the company a “sell” rating in a research note on Friday, February 16th. Needham & Company LLC reiterated a “buy” rating and issued a $97.00 target price on shares of Blueprint Medicines in a research report on Friday. JMP Securities reiterated a “market outperform” rating and issued a $114.00 target price on shares of Blueprint Medicines in a research report on Wednesday, April 10th. Wedbush reiterated an “outperform” rating and issued a $110.00 target price on shares of Blueprint Medicines in a research report on Friday. Finally, Stifel Nicolaus raised their price objective on Blueprint Medicines from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday. Four equities research analysts have rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Blueprint Medicines currently has an average rating of “Hold” and an average price target of $91.57.

Blueprint Medicines Stock Down 1.9 %

Blueprint Medicines stock traded down $1.76 during mid-day trading on Tuesday, reaching $91.34. The stock had a trading volume of 517,046 shares, compared to its average volume of 759,258. The company has a debt-to-equity ratio of 1.60, a quick ratio of 3.66 and a current ratio of 3.76. Blueprint Medicines Co. has a fifty-two week low of $43.89 and a fifty-two week high of $101.00. The stock’s 50-day simple moving average is $90.85 and its 200-day simple moving average is $79.52. The firm has a market capitalization of $5.59 billion, a PE ratio of -10.93 and a beta of 0.63.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. The firm had revenue of $71.96 million during the quarter, compared to analysts’ expectations of $67.34 million. During the same quarter last year, the firm posted ($2.65) earnings per share. The company’s revenue for the quarter was up 85.5% compared to the same quarter last year. On average, sell-side analysts forecast that Blueprint Medicines Co. will post -5.41 EPS for the current fiscal year.

Insider Buying and Selling at Blueprint Medicines

In related news, insider Christopher K. Murray sold 621 shares of Blueprint Medicines stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $93.65, for a total transaction of $58,156.65. Following the transaction, the insider now owns 36,374 shares of the company’s stock, valued at $3,406,425.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Christopher K. Murray sold 621 shares of Blueprint Medicines stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $93.65, for a total transaction of $58,156.65. Following the transaction, the insider now owns 36,374 shares of the company’s stock, valued at $3,406,425.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Christopher K. Murray sold 5,000 shares of Blueprint Medicines stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $100.00, for a total value of $500,000.00. Following the transaction, the insider now directly owns 24,495 shares in the company, valued at approximately $2,449,500. The disclosure for this sale can be found here. Over the last quarter, insiders sold 92,289 shares of company stock valued at $8,314,163. Company insiders own 3.88% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.